GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Biote Corp (NAS:BTMD) » Definitions » Cash Conversion Cycle

Biote (BTMD) Cash Conversion Cycle : 109.60 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Biote Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Biote's Days Sales Outstanding for the three months ended in Mar. 2024 was 14.46.
Biote's Days Inventory for the three months ended in Mar. 2024 was 123.64.
Biote's Days Payable for the three months ended in Mar. 2024 was 28.5.
Therefore, Biote's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 109.60.


Biote Cash Conversion Cycle Historical Data

The historical data trend for Biote's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biote Cash Conversion Cycle Chart

Biote Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
- 30.05 39.74 54.73 77.31

Biote Quarterly Data
Dec19 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 53.09 27.74 35.65 77.34 109.60

Competitive Comparison of Biote's Cash Conversion Cycle

For the Medical Care Facilities subindustry, Biote's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biote's Cash Conversion Cycle Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Biote's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Biote's Cash Conversion Cycle falls into.



Biote Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Biote's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=13.54+89.84-26.07
=77.31

Biote's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=14.46+123.64-28.5
=109.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biote  (NAS:BTMD) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Biote Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Biote's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Biote (BTMD) Business Description

Traded in Other Exchanges
N/A
Address
1875 West Walnut Hill Lane, Suite 100, Irving, TX, USA, 75038
Biote Corp is engaged in bioidentical hormone replacement optimization platform and complementary nutraceutical business. The company offers end-to-end platform that provides practitioners with medical education, training and certification, practice management software, and digital and point-of-care marketing support.
Executives
Mary Elizabeth Conlon officer: General Counsel C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038
Anil K Shrivastava 10 percent owner 200 PARK AVENUE, 17TH FLOOR, NEW YORK NY 10016
Michael David Braner 10 percent owner 200 PARK AVENUE, 17TH FLOOR, NEW YORK NY 10016
Daniel M. Friedberg 10 percent owner C/O SAGARD CAPITAL, 325 GREENWICH AVENUE, GREENWICH CT 06830
325 Capital Llc 10 percent owner 757 THIRD AVENUE, 20TH FLOOR, NEW YORK NY 10017
Mary Joan Puncochar officer: Chief Commercial Officer C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038
Roystone Capital Holdings Llc 10 percent owner 767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Roystone Capital Management Lp 10 percent owner 780 THIRD AVENUE, 41ST FLOOR, NEW YORK NY 10017
Samar Jagat Kamdar officer: Chief Financial Officer 7042 CORONADO AVE., DALLAS TX 75214
Marc D Beer director C/O AEGERION PHARMACEUTICALS, 89 HEADQUARTERS PLAZA, SUITE 1212, MORRISTOWN NJ 07960
Guines Llc 10 percent owner 767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Richard R Barrera 10 percent owner 767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Debra L Morris director 11620 WILSHIRE BOULEVARD, SUITE 1000, LOS ANGELES CA 90025
Andrew R Heyer director, officer: President and Director 501 MADISON AVENUE, FLOOR 5, NEW YORK NY 10019
Teresa Sue Weber director, officer: Chief Executive Officer C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038